Ascelia Pharma AB (OSTO:ACE) ROCE % : -62.27% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ascelia Pharma AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -62.27%.

Ascelia Pharma AB ROCE % Historical Data

The historical data trend for Ascelia Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB ROCE % Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-19.34

-38.86

-47.47

-54.39

-85.78

Ascelia Pharma AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-103.52	-89.16	-127.13	-86.92	-62.27

Ascelia Pharma AB ROCE % Calculation

Ascelia Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-109.607	/	( ( (218.569 - 37.518)	+	(87.072 - 12.568) )	/ 2 )
	=	-109.607	/	( (181.051	+	74.504)	/ 2 )
	=	-109.607	/	127.7775
	=	-85.78 %

Ascelia Pharma AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-49.644	/	( ( (106.369 - 21.42)	+	(87.072 - 12.568) )	/ 2 )
	=	-49.644	/	( ( 84.949	+	74.504 )	/ 2 )
	=	-49.644	/	79.7265
	=	-62.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Ascelia Pharma AB (OSTO:ACE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ascelia Pharma AB ROCE % Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB (OSTO:ACE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7ZA:Germany

Address

Hyllie Boulevard 34, Malmo, SWE, SE-215 32

Website

https://www.ascelia.com

Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo, Sweden, focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer. The company is focused on two clinical-stage product candidates under development: Mangoral and Oncoral.

Ascelia Pharma AB (OSTO:ACE) Headlines

No Headlines